ストックスクリーナーアプリを入手
3.01
0.33%
0.010
アフターアワーズ：
3.01
前日終値:
$3.00
開ける：
$2.98
24時間の取引高:
1.86M
Relative Volume:
1.95
時価総額：
$298.43M
収益：
$9.01M
当期純損益:
$-99.72M
株価収益率:
-0.6633
EPS:
-4.5381
ネットキャッシュフロー:
$-92.85M
1週間 パフォーマンス:
-15.92%
1か月 パフォーマンス:
-27.64%
6か月 パフォーマンス:
-26.41%
1年 パフォーマンス:
-10.95%
1日の値動き範囲:
$2.965
$3.0834
1週間の範囲:
$2.955
$3.58
52週間の値動き範囲:
$2.80
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.01 | 297.44M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Form 4 Oric Pharmaceuticals Inc For: 25 September - Investing.com India
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround - Yahoo Finance
X4 Pharmaceuticals stock falls 9.33 percent to USD 3.11 - AD HOC NEWS
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September - Investing.com India
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Over 5.5M shares in X4 Pharmaceuticals (XFOR) now held by one investor group - stocktitan.net
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to S&P Global BMI Index - marketscreener.com
X4 Pharmaceuticals Inc (48Q0) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
X4 Pharmaceuticals Inc (48Q0) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
X4 Pharmaceuticals stock holds firm before November 5 earnings - AD HOC NEWS
X4 Pharmaceuticals, Inc. (XFOR) Latest Stock News & Headlines - Yahoo Finance
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
XFOR: Phase III enrollment for mavorixafor nears completion, with data and launch expected by early 2029 - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - TradingView
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):